Assessment of the effects of topical sodium cromoglicate on itch and flare in human skin

ISRCTN ISRCTN35671014
DOI https://doi.org/10.1186/ISRCTN35671014
Protocol serial number HHSOT.01
Sponsor Hewlett Healthcare Ltd (UK)
Funder Hewlett Healthcare Ltd (UK)
Submission date
02/09/2010
Registration date
21/09/2010
Last edited
21/09/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Martin Church
Scientific

Dermatopharmacology Unit
South Block 825
Southamptom General Hospital
Southampton
SO16 6YD
United Kingdom

Email mkc@soton.ac.uk

Study information

Primary study designInterventional
Study designRandomised double-blind vehicle controlled intra-subject trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleTo assess the effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial
Study objectivesThe intradermal injection of histamine in human skin results in a weal, flare and increased blood flux accompanied by severe itching. We have previously shown that the chromone, nedocromil sodium when introduced into the skin using iontophoresis can reduce the severity of the itch and the size of the flare, but with no effect on the weal or blood flux. We hypothesise that the related chromone, sodium cromoglicate will have the same effect both when introduced by iontophoresis and when applied topically to the skin using a new cutaneous emulsion, Altoderm.
Ethics approval(s)Southampton and South West Hampshire Research Ethics Committee approved in March 2000 (ref: 00/100)
Health condition(s) or problem(s) studiedItch and flare in human skin
Intervention1. 4% sodium cromoglicate dissolved in reversed osmosis purified water or reversed osmosis purified water, delivered by iontophoresis to skin.
Total duration of treatment: single treatment only
Total duration of follow-up: one hour after study completion
2. 4% sodium cromoglicate cutaneous emulsion or vehicle, applied topically to skin
Total duration of treatment: three days of treatment before study day
Total duration of follow-up: one hour after last treatment
3. 1%, 2% 4% sodium cromoglicate cutaneous emulsion or vehicle, applied topically to skin
Total duration of treatment: three days of treatment before study day
Total duration of follow-up: one hour after last treatment

All subjects challenged with intrademal histamine, 20 microlitres of 1 micromolar.
Intervention typeDrug
PhasePhase I/II
Drug / device / biological / vaccine name(s)Sodium cromoglicate
Primary outcome measure(s)

1. Change in severity of itch measured every 20 seconds for 5 minutes after injection of histamine using 100 mm Visual Analogue Scale
2. Change in area of flare and blood flux using scanning laser Doppler imaging
3. Change in area of weal using planimetry

Key secondary outcome measure(s)

No secondary outcome measures

Completion date01/08/2000

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration60
Key inclusion criteria1. Healthy adult volunteers (18 - 65 years old), male only
2. Recruited from the staff and students of Southampton University Medical School and Southampton General Hospital
Key exclusion criteria1. Pregnancy
2. Presence of skin disease
3. Taking of drugs which may interfere with the study, including corticosteroids, antihistamines, antidepressants and psychotropic drugs
Date of first enrolment01/04/2000
Date of final enrolment01/08/2000

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Dermatopharmacology Unit
Southampton
SO16 6YD
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/02/2001 Yes No
Results article results 01/03/2004 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes